 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of [0m
[34mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase the risk of [0m
[32mgastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"warfarin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: WARFARIN: boxed_warning: WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [0m[31m . Perform regular monitoring of INR in all treated patients [0m[31m . Drugs, dietary changes, and [0m
[31mother factors affect INR levels achieved with warfarin sodium therapy [0m[31m . Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m
[31mWARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Warfarin sodium can cause major or fatal bleeding. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Perform regular monitoring of INR in all treated [0m
[31mpatients. [0m[1;31m([0m[31m [0m[1;31m2.1[0m[31m [0m[1;31m)[0m[31m Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m7[0m[31m [0m[1;31m)[0m[31m Instruct patients about prevention measures to [0m
[31mminimize risk of bleeding and to report signs and symptoms of bleeding. WARFARIN: boxed_warning: [0m[1;31m([0m[31m [0m[1;31m17[0m[31m [0m[1;31m)[0m[31m         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: openfda: spl_set_id         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, [0m
[31mzileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, [0m
[31mcilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenav WARFARIN: [0m
[31mdrug_interactions: ir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, [0m
[31mritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, [0m
[31mpioglitazone, prednisone, rifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN: drug_interactions: [0m
[31mBecause bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: drug_interactions: Table [0m[1;31m3[0m[31m: Drugs [0m
[31mthat Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel,[0m
[31mdipyridamole, prasugrel, ticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, [0m
[31moxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlaf WARFARIN: [0m
[31mdrug_interactions: axine, vilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic [0m
[31mstudies have not shown consistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin. [0m
[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m Products and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, well-controlled studies evaluating the potential for [0m
[31mmetabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active [0m
[31mingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals may cause bleeding events when taken alone [0m[1;31m([0m[31me.g. [0m
[31mWARFARIN: drug_interactions: garlic and Ginkgo biloba[0m[1;31m)[0m[31m and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant [0m
[31meffects of warfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium [0m[1;31m([0m[31me.g., co-enzyme Q [0m[1;31m10[0m[31m , St. Johnâ€™s wort, ginseng[0m[1;31m)[0m[31m. Some botanicals and foods can interact with [0m
[31mwarfarin sodium through CYP450 interactions [0m[1;31m([0m[31me.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. Johnâ€™s wort[0m[1;31m)[0m[31m. The amount of vitamin K in food may affect therapy with warfarin sodium. Advise [0m
[31mpatients taking warfarin sodium to eat a normal, balanced diet maintaining a consistent amount of vitamin K. Patients taking warfarin sodium should avoid drastic changes in dietary habits, such as [0m
[31meating large amounts of green leafy vegetables.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: spl_medguide_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mwidth[0m[31m=[0m[31m"1000px"[0m[31m><col/><col/><tbody><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><tbody><tr><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Lrule [0m
[31mRrule"[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Warfarin <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31mwar&apos; far in[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> Sodium <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m>[0m[1;31m([0m[31msoe&apos; dee um[0m[1;31m)[0m[31m<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m> [0m
[31mTablets<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule Rrule"[0m[31m/[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Lrule [0m
[31mRrule"[0m[31m><content style WARFARIN: spl_medguide_table: [0m[31mCode[0m[31m=[0m[31m"bold"[0m[31m>What is the most important information I should know about warfarin sodium tablets?<[0m[31m/[0m[31mcontent[0m[31m><paragraph>Warfarin sodium tablets can [0m
[31mcause bleeding which can be serious and sometimes lead to death. This is because warfarin sodium tablets are a blood thinner medicine that lowers the chance of blood clots forming in your body. [0m
[31mWARFARIN: spl_medguide_table: <[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>You may have a higher risk of bleeding if you take warfarin sodium tablets and: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Circle"[0m[31m><item>are [0m[1;31m65[0m[31m years of age or older <[0m[31m/[0m[31mitem[0m[31m><item>have a history of stomach or intestinal bleeding <[0m[31m/[0m[31mitem[0m[31m><item>have high blood pressure [0m[1;31m([0m[31mhypertension[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have a history of [0m
[31mstroke, or &#x201C;mini-stroke&#x201D; [0m[1;31m([0m[31mtransient ischemic attack or TIA[0m[1;31m)[0m[31m <[0m[31m/[0m[31mitem[0m[31m><item>have serious heart disease <[0m[31m/[0m[31mitem[0m[31m><item>have a low blood count or cancer <[0m[31m/[0m[31mitem[0m[31m><item>have had trauma, such as an[0m
[31maccident or surgery <[0m[31m/[0m[31mitem[0m[31m><item>have kidney problems <[0m[31m/[0m[31mitem[0m[31m><item>take other medicines that increase your risk of bleeding, including: <list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Square"[0m[31m><item>a medicine [0m
[31mthat contains heparin <[0m[31m/[0m[31mitem[0m[31m WARFARIN: spl_medguide_table: ><item>other medicines to prevent or treat blood clots <[0m[31m/[0m[31mitem[0m[31m><item>non-steroidal anti-inflammatory drugs [0m[1;31m([0m[31mNSAIDs[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><item>take warfarin sodium for a long time. Warfarin sodium is the active ingredient in warfarin sodium tablets. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above. [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Many other medicines can interact with warfarin sodium tablets and affect the dose you need or increase warfarin sodium tablets side effects. Do not change or stop any[0m
[31mof your medicines or start any new medicines before you talk to your healthcare provider. <[0m[31m/[0m[31mparagraph[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Do not take other medicines that contain warfarin sodium [0m
[31mwhile taking warfarin sodium tablets. WARFARIN: spl_medguide_table: content><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Get your regular blood test to check[0m
[31mfor your response to warfarin sodium tablets. <[0m[31m/[0m[31mcontent[0m[1;31m>[0m[31mThis blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR [0m
[31mnumbers are best for you. Your dose of warfarin sodium tablets will be adjusted to keep your INR in a target range for you.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: clinical_studies: The results of this study are presented in Table [0m[1;31m6[0m[31m . Table [0m[1;31m6[0m[31m: Prospective, Open-Label Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart [0m
[31mValves Event Moderate Warfarin Therapy INR [0m[1;31m2.65[0m[31m High Intensity Warfarin Therapy INR [0m[1;31m9[0m[31m Thromboembolism [0m[1;31m4[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m3.7[0m[31m/[0m[1;31m100[0m[31m py Major Bleeding [0m[1;31m0.95[0m[31m/[0m[1;31m100[0m[31m py [0m[1;31m2.1[0m[31m/[0m[1;31m100[0m[31m py py = patient years In a randomized trial[0m
[31min [0m[1;31m210[0m[31m patients comparing two intensities of warfarin therapy [0m[1;31m([0m[31mINR [0m[1;31m2[0m[31m to [0m[1;31m2.25[0m[31m vs. INR [0m[1;31m2.5[0m[31m to [0m[1;31m4[0m[1;31m)[0m[31m for a three month period following tissue heart valve replacement, thromboembolism occurred with similar [0m
[31mfrequency in the two groups [0m[1;31m([0m[31mmajor embolic events [0m[1;31m2[0m[31m% vs. [0m[1;31m1.9[0m[31m%, respectively, and minor embolic events [0m[1;31m10.8[0m[31m% vs. [0m[1;31m10.2[0m[31m%, respectively[0m[1;31m)[0m[31m. WARFARIN: clinical_studies: Major hemorrhages occurred in [0m[1;31m4.6[0m[31m% of [0m
[31mpatients in the higher intensity INR group compared to zero in the lower intensity INR group. [0m[1;31m14.3[0m[31m Myocardial Infarction WARIS [0m[1;31m([0m[31mThe Warfarin Re-Infarction Study[0m[1;31m)[0m[31m was a double-blind, randomized study [0m
[31mof [0m[1;31m1214[0m[31m patients [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m weeks post-infarction treated with warfarin to a target INR of [0m[1;31m2.8[0m[31m to [0m[1;31m4.8[0m[31m. The primary endpoint was a composite of total mortality and recurrent infarction. A secondary [0m
[31mendpoint of cerebrovascular events was assessed. Mean follow-up of the patients was [0m[1;31m37[0m[31m months. The results for each endpoint separately, including an analysis of vascular death, are provided in Table [0m
[1;31m7[0m[31m . WARFARIN: clinical_studies: Table [0m[1;31m7[0m[31m: WARIS â€“ Endpoint Analysis of Separate Events % Risk Warfarin Placebo Reduction Event [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m [0m[1;31m([0m[31mN = [0m[1;31m607[0m[1;31m)[0m[31m RR [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m [0m[1;31m([0m[31m p -value[0m[1;31m)[0m[31m Total Patient Years of [0m
[31mFollow-up [0m[1;31m2018[0m[31m [0m[1;31m1944[0m[31m Total Mortality [0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m123[0m[31m [0m[1;31m([0m[1;31m6.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.76[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m0.97[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.030[0m[1;31m)[0m[31m Vascular Death [0m[1;31m82[0m[31m [0m[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m5.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.78[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m, [0m[1;31m1.02[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.068[0m[1;31m)[0m[31m Recurrent MI [0m[1;31m82[0m[31m [0m
[1;31m([0m[1;31m4.1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m124[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.66[0m[31m [0m[1;31m([0m[1;31m0.51[0m[31m, [0m[1;31m0.85[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0[0m[31m. WARFARIN: clinical_studies: [0m[1;31m001[0m[1;31m)[0m[31m Cerebrovascular Event [0m[1;31m20[0m[31m [0m[1;31m([0m[1;31m1[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m/[0m[1;31m100[0m[31m py[0m[1;31m)[0m[31m [0m[1;31m0.46[0m[31m [0m[1;31m([0m[1;31m0.28[0m[31m, [0m[1;31m0.75[0m[1;31m)[0m[31m [0m[1;31m54[0m[31m [0m[1;31m([0m[31mp = [0m[1;31m0.002[0m[1;31m)[0m[31m RR = Relative risk; [0m
[31mRisk reduction = [0m[1;31m([0m[1;31m1[0m[31m - RR[0m[1;31m)[0m[31m; CI = Confidence interval; MI = Myocardial infarction; py = patient years WARIS II [0m[1;31m([0m[31mThe Warfarin, Aspirin, Re-Infarction Study[0m[1;31m)[0m[31m was an open-label, randomized study of [0m[1;31m3630[0m[31m [0m
[31mpatients hospitalized for acute myocardial infarction treated with warfarin to a target INR [0m[1;31m2.8[0m[31m to [0m[1;31m4.2[0m[31m, aspirin [0m[1;31m160[0m[31m mg per day, or warfarin to a target INR [0m[1;31m2[0m[31m to [0m[1;31m2.5[0m[31m plus aspirin [0m[1;31m75[0m[31m mg per day prior to[0m
[31mhospital discharge. The primary endpoint was a composite of death, nonfatal reinfarction, or thromboembolic stroke. WARFARIN: clinical_studies: The mean duration of observation was approximately [0m[1;31m4[0m[31m [0m
[31myears. The results for WARIS II are provided in Table [0m[1;31m8[0m[31m . Table [0m[1;31m8[0m[31m: WARIS II â€“ Distribution of Events According to Treatment Group Event Aspirin [0m[1;31m([0m[31mN = [0m[1;31m1206[0m[1;31m)[0m[31m Warfarin [0m[1;31m([0m[31mN = [0m[1;31m1216[0m[1;31m)[0m[31m Aspirin plus Warfarin [0m[1;31m([0m[31mN [0m
[31m= [0m[1;31m1208[0m[1;31m)[0m[31m Rate Ratio [0m[1;31m([0m[1;31m95[0m[31m% CI[0m[1;31m)[0m[31m p -value No. of Events Major Bleeding a [0m[1;31m8[0m[31m [0m[1;31m33[0m[31m [0m[1;31m28[0m[31m [0m[1;31m3.35[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m4.00[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Minor Bleeding d [0m[1;31m39[0m[31m [0m[1;31m103[0m[31m [0m[1;31m133[0m[31m [0m[1;31m3.21[0m[31m b [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND [0m[1;31m2.55[0m[31m c [0m[1;31m([0m[31mND[0m[1;31m)[0m[31m ND Composite Endpoints e [0m[1;31m241[0m[31m [0m[1;31m203[0m[31m [0m[1;31m181[0m[31m [0m
[1;31m0.81[0m[31m [0m[1;31m([0m[1;31m0.69[0m[31m to [0m[1;31m0.95[0m[1;31m)[0m[31m b [0m[1;31m0.03[0m[31m [0m[1;31m0.71[0m[31m [0m[1;31m([0m[1;31m0.60[0m[31m to [0m[1;31m0.83[0m[1;31m)[0m[31m c [0m[1;31m0[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Warfarin sodium can cause major or fatal bleeding, which includes the risk of gastrointestinal bleeding. Patients with a history of stomach or intestinal bleeding may have a higher risk of [0m
[32mbleeding when taking warfarin. Therefore, it can be inferred that warfarin may increase the risk of gastrointestinal ulcer hospitalization due to its bleeding risk, although the extracts do not [0m
[32mprovide specific data on hospitalization rates for gastrointestinal ulcers.[0m

[32mSOURCE: WARFARIN label[0m
[32mEXTRACT_START_END: Warfarin sodium can cause [0m[32m...[0m[32m signs and symptoms of bleeding.[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Warfarin sodium can cause major or fatal [0m
[34mbleeding, which includes the risk of gastrointestinal bleeding. Patients with a history of stomach or intestinal bleeding may have a higher risk of bleeding when taking warfarin. Therefore, it can be [0m
[34minferred that warfarin may increase the risk of gastrointestinal ulcer hospitalization due to its bleeding risk, although the extracts do not provide specific data on hospitalization rates for [0m
[34mgastrointestinal ulcers.[0m

[34mSOURCE: WARFARIN label[0m
[34mEXTRACT_START_END: Warfarin sodium can cause [0m[34m...[0m[34m signs and symptoms of bleeding.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if WARFARIN increases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Warfarin sodium can cause major or fatal bleeding, which includes the risk of gastrointestinal bleeding. Patients with a history of stomach or intestinal bleeding may [0m
[32mhave a higher risk of bleeding when taking warfarin."[0m[32m,[0m
[32m      [0m[32m"Although the FDA label does not provide specific data on hospitalization rates for gastrointestinal ulcers, it can be inferred that warfarin may increase the risk of gastrointestinal ulcer [0m
[32mhospitalization due to its bleeding risk."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Warfarin may increase the risk of gastrointestinal ulcer hospitalization due to its association with an increased risk of gastrointestinal bleeding."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does WARFARIN increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if WARFARIN increases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Warfarin sodium can cause major or fatal bleeding, which includes the risk of gastrointestinal bleeding. Patients with a history of stomach or intestinal bleeding may [0m
[34mhave a higher risk of bleeding when taking warfarin."[0m[34m,[0m
[34m      [0m[34m"Although the FDA label does not provide specific data on hospitalization rates for gastrointestinal ulcers, it can be inferred that warfarin may increase the risk of gastrointestinal ulcer [0m
[34mhospitalization due to its bleeding risk."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Warfarin may increase the risk of gastrointestinal ulcer hospitalization due to its association with an increased risk of gastrointestinal bleeding."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does WARFARIN increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if WARFARIN increases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that Warfarin sodium can cause major or fatal bleeding, which includes the risk of gastrointestinal bleeding. Patients with a history of stomach or intestinal bleeding may have[0m
[31ma higher risk of bleeding when taking warfarin.[0m
[1;31m3[0m[31m. Although the FDA label does not provide specific data on hospitalization rates for gastrointestinal ulcers, it can be inferred that warfarin may increase the risk of gastrointestinal ulcer [0m
[31mhospitalization due to its bleeding risk.[0m
[31m        -----[0m
[31m        Final answer: Warfarin may increase the risk of gastrointestinal ulcer hospitalization due to its association with an increased risk of gastrointestinal bleeding.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning process appears to be sound. The user has taken information from FDAHandler regarding the risk of gastrointestinal bleeding associated with Warfarin and logically [0m
[32minferred that this could lead to an increased risk of hospitalization for gastrointestinal ulcers. The user has correctly noted the absence of specific hospitalization rate data but has made a [0m
[32mreasonable inference based on the known side effects of the drug. There is no specific flaw in this reasoning."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning process appears to be sound. The user has taken information from FDAHandler regarding the risk of gastrointestinal bleeding associated with Warfarin and logically [0m
[34minferred that this could lead to an increased risk of hospitalization for gastrointestinal ulcers. The user has correctly noted the absence of specific hospitalization rate data but has made a [0m
[34mreasonable inference based on the known side effects of the drug. There is no specific flaw in this reasoning."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning process appears to be sound. The user has taken information from FDAHandler regarding the risk of gastrointestinal bleeding associated with Warfarin and logically [0m
[31minferred that this could lead to an increased risk of hospitalization for gastrointestinal ulcers. The user has correctly noted the absence of specific hospitalization rate data but has made a [0m
[31mreasonable inference based on the known side effects of the drug. There is no specific flaw in this reasoning.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mWarfarin may increase the risk of gastrointestinal ulcer hospitalization due to its association with an increased risk of gastrointestinal bleeding. This inference is based on the information provided[0m
[32mby FDAHandler, which states that Warfarin sodium can cause major or fatal bleeding, including gastrointestinal bleeding. Patients with a history of stomach or intestinal bleeding may have a higher [0m
[32mrisk of bleeding when taking Warfarin. While the FDA label does not provide specific data on hospitalization rates for gastrointestinal ulcers, the increased risk of gastrointestinal bleeding suggests[0m
[32ma potential increase in the risk of hospitalization for gastrointestinal ulcers.[0m
